Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of S-1226 composed of perflubron with ascending doses
of carbon dioxide (4%, 8%, and 12% CO2) administered over 2 minute nebulisation to healthy
subjects.